FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to a method for producing autologous fibrin with controlled fibrinogen content. A method for producing autologous fibrin with controlled fibrinogen content without the use of exogenous thrombin includes blood sampling with sodium citrate, obtaining platelet-rich blood plasma by centrifugation, isolation of precipitate from blood plasma by ethanol precipitation with a low ethanol content, incubation with constant stirring and centrifugation, concentration control fibrinogen in the precipitate by diluting with a buffer, adding a solution of calcium chloride under certain conditions.
EFFECT: method makes it possible to obtain an autologous, biocompatible and safe fibrin for regenerative and tissue engineering, having a controlled composition and having a high integration with the host organism.
1 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IN VITRO PRODUCTION OF A PERSONALIZED CELL-POPULATED VASCULAR PROSTHESIS | 2021 |
|
RU2764051C1 |
| METHOD FOR CREATING A BIORESORBABLE CELLULAR SCAFFOLD BASED ON FIBRIN OF BLOOD PLASMA | 2017 |
|
RU2653434C1 |
| DIAGNOSTICS OF THROMBOEMBOLIC VEIN DISEASES BY DETERMINATION OF CONTENT OF D-DIMERS AND SOLUBLE FIBRIN | 2007 |
|
RU2475760C2 |
| METHOD OF AUTOGRAFT FIXATION IN MYRINGOPLASTY | 2019 |
|
RU2708038C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF SOLUBLE FIBRIN | 2001 |
|
RU2310200C2 |
| DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
| METHOD FOR DETERMINATION OF FUNCTIONAL FIBRINOGEN | 2017 |
|
RU2669796C1 |
| DETERMINING HUMAN ERYTHROCYTE SENSITIVITY TO LYSIS WITH COMPLEMENT SYSTEM ACTIVATION ON THROMBIN PATHWAY | 2019 |
|
RU2696981C1 |
| FIBRINOGEN CONTENT ANALYSIS | 2012 |
|
RU2619256C2 |
| METHOD OF OBTAINING FIBRIN GLUE FROM DONOR PLASMA AND ITS IDENTIFICATION | 2023 |
|
RU2803272C2 |
